BRAF and neoplasm: In mCRC, the paradigm of negative hyperselection, combined with left-sided tumor location, has consistently identified patients deriving the greatest benefit from EGFR inhibition.21, 22, 23, 24, 25 Furthermore, novel EGFR-targeting agents, such as bispecific EGFR-MET targeting antibodies, have given encouraging preliminary results in RAS and BRAF wild-type mCRC,33 and may be used, in the future, to enhance EGFR inhibition in curative-intent strategies, upon appropriate molecular selection.